Reactivity profile of anti-factor VIII antibodies with designed synthetic peptides mimicking epitopes of the C2 and a1 domains

British Journal of Haematology

Volumn 141, Issue 5, 2008, Pages 708-715

  Chaves, D G ^a,b   Velloso Rodrigues, C ^b,c   Moreau, V ^d   Nguyen, C ^d   Villard, S ^d   Belisario A R ^b,c   Granier, C ^d   Santoro, M M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Hemominas Foundation   (Brazil)

^c PONTIFICAL CATHOLIC UNIVERSITY OF MINAS GERAIS   (Brazil)

^d CNRS   (France)

Author keywords

C2 domain; Epitope; Factor VIII inhibitors; Purification; Synthetic peptides

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 8; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; SEPHAROSE; SYNTHETIC PEPTIDE;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA A; HUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; SCREENING;

ANTIGEN-ANTIBODY REACTIONS; AUTOANTIBODIES; BINDING, COMPETITIVE; CHROMATOGRAPHY, AFFINITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNODOMINANT EPITOPES; MALE; PEPTIDE FRAGMENTS;

EID: 43449127809     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2008.07043.x     Document Type: Article

References (34)

1. Di Giambattista, M., Branckaert, T., Hougardy, V., Kemball-Cook, G. Laub, R. (2007) In silico prediction of FVIII epitopes recognised by natural autoantibodies in polyvalent immunoglobulin concentrates. Molecular Immunology, 44, 1903 1913.
2. Dimichele, D.M. (2002) Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia, 8, 280 287.
3. Ehrenforth, S., Kreuz, W., Scharrer, I., Linde, R., Funk, M., Güngör, T., Krackhardt, B. Kornhuber, B. (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet, 339, 594 598.
4. Felsenstein, J. (1989) PHYLIP - Phylogeny Inference Package (Version 3.2). Cladistics, 5, 164 166.
5. Fulcher, C.A., De Graaf Mahoney, S., Roberts, J.R., Kasper, C.K. Zimmerman, T.S. (1985) Localization of human factor VIII inhibitor epitopes to two polypeptide fragments. Proceedings of the National Academy of Sciences of the United States of America, 82, 7728 7732.
6. Fulcher, C., De Graaf Mahoney, S. Zimmerman, T. (1987) Factor VIII inhibitor IgG subclass and fVIII polypeptide specificity determined by immunoblotting. Blood, 69, 1475 1480.
7. Gausepohl, H., Boulin, C., Kraft, M. Frank, R.W. (1992) Automated multiple peptide synthesis. Peptide Research, 5, 315 320.
8. Gilles, J.G., Arnout, J., Vermylen, J. Saint-Remy, J.M. (1993) Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood, 82, 2452 2461.
9. Guillet, B., Kriaa, F., Huysse, M.G., Proulle, V., George, C., Tchernia, G., D'oiron, R., Laurian, Y., Charpentier, B., Lambert, T. Dreyfus, M. (2001) Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia. British Journal of Haematology, 114, 837 844.
10. Hedner, U., Glazer, S. Falch, J. (1993) Recombinant activated factor VII in the treatment of bleeding episodes in patients with inherited and acquired bleeding disorders. Transfusion Medicine Reviews, 7, 78 83.
11. Hodge, G., Saxon, B. Revesz, T. (2006) Effect of factor VIII concentrate on leucocyte cytokine receptor expression in vitro: relevance to inhibitor formation and tolerance induction. Haemophilia, 12, 133 139.
12. Hoyer, L.W. (1987) Molecular pathology and immunology of factor VIII (hemophilia A and factor VIII inhibitors). Human Pathology, 18, 153 161.
13. Jacquemin, M.G., Desqueper, B.G., Benhida, A., Vander Elst, L., Hoylaerts, M.F., Bakkus, M., Thielemans, K., Arnout, J., Peerlinck, K., Gilles, J.G., Vermylen, J. Saint-Remy, J.M. (1998) Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood, 92, 496 506.
14. Kabsch, W. Sander, C. (1983) Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers, 22, 2577 2637.
15. Kopecky, E.M., Greinstetter, S., Pabinger, I., Buchacher, A., Romisch, J. Jungbauer, A. (2005) Combinatorial peptides directed to inhibitory antibodies against human blood clotting factor VIII. Thrombosis and Haemostasis, 94, 933 941.
16. Kopecky, E.M., Greinstetter, S., Pabinger, I., Buchacher, A., Romisch, J. Jungbauer, A. (2006a) Effect of oriented or random PEGylation on bioactivity of a factor VIII inhibitor blocking peptide. Biotechnology and Bioengineering, 93, 647 655.
17. Kopecky, E.M., Greinstetter, S., Pabinger, I., Buchacher, A., Romisch, J. Jungbauer, A. (2006b) Mapping of FVIII inhibitor epitopes using cellulose-bound synthetic peptide arrays. Journal of Immunological Methods, 308, 90 100.
18. Laune, D., Molina, F., Ferrieres, G., Villard, S., Bes, C., Rieunier, F., Chardes, T. Granier, C. (2002) Application of the Spot method to the identification of peptides and amino acids from the antibody paratope that contribute to antigen binding. Journal of Immunological Methods, 267, 53 70.
19. Lavigne-Lissalde, G., Schved, J.F., Granier, C. Villard, S. (2005) Anti-factor VIII antibodies: a 2005 update. Thrombosis and Haemostasis, 94, 760 769.
20. Lusher, J.M., Arkin, S., Abildgaard, C.F. Schwartz, R.S. (1993) Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate previously untreated patient study group. The New England Journal of Medicine, 328, 453 459.
21. Orsini, F., Rotschild, C., Beurrier, P., Faradji, A., Goudemand, J. Polack, B. (2005) Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica, 90, 1288 1290.
22. Palmer, D.S., Dudani, A.K., Drouin, J. Ganz, P.R. (1997) Identification of novel factor VIII inhibitor epitopes using synthetic peptide arrays. Vox Sanguinis, 72, 148 161.
23. Pratt, K.P., Shen, B.W., Takeshima, K., Davie, E.W., Fujikawa, K. Stoddard, B.L. (1999) Structure of the C2 domain of human factor VIII at 1.5 Å resolution. Nature, 402, 439 442.
24. Raut, S., Villard, S., Grailly, S., Gilles, J.G., Granier, C., Saint-Remy, J.R. Barrowcliffe, T.W. (2003) Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor. Thrombosis and Haemostasis, 90, 385 397.
25. Rocino, A., Santagostino, E., Mancuso, M.E. Mannucci, P.M. (2006) Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors. Haematologica, 91, 558 561.
26. Sahud, M.A., Pratt, K.P., Zhukov, O., Qu, K. Thompson, A.R. (2007) ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay. Haemophilia, 13, 317 322.
27. Scandella, D. (1999) Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies. Vox Sanguinis, 77, 17 20.
28. Scandella, D., Gilbert, G.E., Shima, M., Nakai, H., Eagleson, C., Felch, M., Prescott, R., Rajalakshmi, K.J., Hoyer, L.W. Saenko, E. (1995) Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood, 86, 1811 1819.
29. Sunagawa, T., Uezu, Y., Kadena, K., Tokuyama, K., Kinjo, F. Saito, A. (1999) Successful treatment of a non-haemophiliac patient with inhibitor to factor VIII by double-filtration plasmapheresis. British Journal of Haematology, 104, 465 467.
30. Tam, J.P., Wu, C., Liu, W. Zhang, J.W. (1991) Disulfide bond formation in peptides by dimethyl sulfoxide. Scope and applications. Journal of American Chemical Society, 113, 6657 6662.
31. Towfighi, F., Gharagozlou, S., Sharifian, R.A., Kazemnejad, A., Esmailzadeh, K., Managhchi, M.R. Shokri, F. (2005) Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. Acta Haematologica, 114, 84 90.
32. Verbruggen, B., Novakova, I., Wessels, H., Boezeman, J., Van Den Berg, M. Mauser-Bunschoten, E. (1995) The Nijmegen modification of Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thrombosis and Haemostasis, 73, 247 251.
33. Villard, S., Piquer, D., Raut, S., Léonetti, J., Saint-Remy, J. Granier, C. (2002) Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. The Journal of Biological Chemistry, 277, 27232 27239.
34. Villard, S., Lacroix-Desmazes, S., Kieber-Emmons, T., Piquer, D., Grailly, S., Benhida, A., Kaveri, S.V., Saint-Remy, J. Granier, C. (2003) Peptide decoys selected by phage display block in vitro and in vivo activity of a human anti-FVIII inhibitor. Blood, 102, 949 952.